Clinical Practice Update

 

HPS Pharmacies wish to advise that the transition period for the International Harmonisation of Ingredient Names has begun. This project, initiated by the Therapeutic Goods Administration (TGA), is designed to reduce confusion by aligning the Australian Approved Name (ANN) of medicines with the International Nonproprietary Name (INN).

You may start to notice changes to medicine labelling as new packaging makes its way onto shelves. Some of these changes are minor spelling changes that do not affect the pronunciation of the medicine. Other changes are more significant and will require dual labelling until 2023.

Adrenaline and noradrenaline are notable exceptions. Due to the potential risk of patient harm from errors related to these medications, adrenaline and noradrenaline will remain the AAN. However, the respective INNs, epinephrine and norepinephrine, will be added to medication labels during the transition period and remain indefinitely.

Some examples are shown below, the complete list of all 227 changes can be found on the TGA website:

Change

Previous Name

New Name

Adrenaline and noradrenaline (indefinite dual labelling)

Adrenaline

Adrenaline (epinephrine)

Noradrenaline acid tartrate

Noradrenaline (norepinephrine) acid tartrate monohydrate

Minor spelling change

Amoxycillin

Amoxicillin

Cephazolin

Cefazolin

Hydration change only

Codeine phosphate

Codeine phosphate hemihydrate

Significant change
(will require dual labelling until 2023)

Colaspase

Asparaginase (colaspase)

Dothiepin hydrochloride

Dosulepin (dothiepin) hydrochloride

Frusemide

Furosemide (frusemide)

Glycopyrrolate

Glycopyrronium bromide (glycopyrrolate)

Hydroxyurea

Hydroxycarbamide (hydroxyurea)

Lignocaine

Lidocaine (lignocaine)

Other significant changes

Hexamine hippurate

Methenamine hippurate

Insulin – human

Insulin

Thyroxine sodium

Levothyroxine sodium

 

 

 

 

 

 

 

 

 

 

 

Laminated posters detailing some of the more common medication changes are available from your Director of Pharmacy/Pharmacy Manager on request. A lecture providing greater detail on these changes, and how it will affect clinical practice, is also available as part of the HPS Pharmacies Lecture Series Programme. Please contact your Pharmacist at HPS Pharmacies if you would like to organise an education session.

Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates